文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

转移性宫颈癌患者的局部区域治疗:剂量递增策略的获益

Locoregional Treatment in Patients With Metastatic Cervical Cancer: Benefit of Dose Escalation Strategies.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-08-14

该研究回顾性分析了Gustave Roussy研究所164例接受外照射放疗及影像引导自适应近距离放疗(IGABT)加量的转移性宫颈癌患者,中位随访36个月,3年总生存率55.5%、无进展生存率40.6%、局部控制率90%;多因素分析显示D90CTVHR≥80 Gy与更好的总生存显著相关(HR 0.96,95%CI 0.94-0.98,P<.001)。

要点

  • 转移性宫颈癌接受IGABT加量后3年局部控制率达90%,总生存率55.5%。
  • D90CTVHR≥80 Gy与更好的总生存显著相关(HR 0.96,95%CI 0.94-0.98,P<.001)。
  • 毒性以轻中度为主,3级晚期泌尿毒性2%、3级直肠炎1例、晚期2级阴道后遗症7%。

核心结论

  • IGABT允许对盆腔外扩散的宫颈癌患者进行剂量递增并获得高局部控制率,且显示了生存的剂量/效应关系。
  • 由于远处事件发生频率高,作者认为应在这类患者中更特异地测试全身强化治疗。

研究设计与样本

  • 回顾性检查了Gustave Roussy研究所连续收治的转移性宫颈癌患者医疗记录,这些患者在一线治疗中接受外照射放疗和IGABT加量。
  • 根据肿瘤部位,患者接受盆腔±腹主动脉旁外照射放疗;对有内脏或膈上淋巴结转移者,通常在3周期化疗后行放化疗。
  • 所有患者均接受磁共振成像引导的近距离放疗加量,旨在提高高危临床靶区(CTVHR)的剂量。
  • 共纳入164例患者,其中76.2%有腹主动脉旁淋巴结扩散无远处转移(N2),23.8%有远处转移部位(M1)。

主要发现

  • N2组与M1组之间生存无统计学显著差异。
  • 中位随访36个月,3年总生存率55.5%(95%CI 48%-64%),3年无进展生存率40.6%(95%CI 38%-54%),3年局部控制率90%(95%CI 85%-96%)。
  • 多因素分析中,D90CTVHR剂量≥80 Gy与更好的总生存显著相关(HR 0.96,95%CI 0.94-0.98,P<.001)。
  • 大多数毒性为轻至中度,3级晚期泌尿毒性2%,晚期2级阴道后遗症7%,3级直肠炎1例。
  • 随访期间,2例无局部复发的患者发生直肠阴道瘘。

关键数值与推荐

  • D90CTVHR剂量≥80 Gy与更好的总生存显著相关(HR 0.96,95%CI 0.94-0.98,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this work was to examine the benefit of an intensive locoregional treatment including an image guided adaptive brachytherapy (IGABT) among patients with cervical cancer and extrapelvic extension. METHODS AND MATERIALS: Medical records of consecutive patients with a metastatic cervical cancer and receiving external beam radiation therapy and IGABT boost in Gustave Roussy Institute as part of their first line of treatment were examined. Depending on tumor sites, patients received pelvic ± para-aortic external beam radiation therapy. For those with visceral or supradiaphragmatic lymph node metastases, chemoradiation was delivered after usually 3 cycles of chemotherapy. All patients received a brachytherapy boost, guided by magnetic resonance imaging and aimed at increasing the dose to the high-risk clinical target volume (CTVHR). Local control (LC), patient overall survival (OS), progression-free survival, and radiation therapy-related side effects were examined, and prognostic factors were searched. RESULTS: One hundred sixty-four patients were included; 76.2% had para-aortic lymph node extension without distant metastasis (N2) and 23.8% had distant metastatic sites (M1). There was not a statistically significant difference in survival between both groups. With a median follow-up of 36 months, OS, progression-free survival, and LC at 3 years were 55.5% (95% CI, 48%-64%), 40.6% (95% CI, 38%-54%), and 90% (95% CI, 85%-96%), respectively. In multivariate analysis, a D90CTVHR dose ≥80 Gy was significant for better OS (hazard ratio, 0.96; 95% CI, 0.94-0.98; P < .001). Most toxicities were mild to moderate, with 2% grade 3 late urinary toxicity, 7% late grade 2 vaginal sequelae, and 1 grade 3 proctitis. During follow-up, rectovaginal fistula occurred in 2 patients without local relapse. CONCLUSIONS: IGABT permits dose escalation and high LC rates for patients with cervical cancer and extrapelvic extension. Dose/effect relationships for survival were shown. Because of high frequency of distant events, systemic intensification should be tested more specifically among these patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Laville A, Ka K, El-Ayachi R, et al. Locoregional Treatment in Patients With Metastatic Cervical Cancer: Benefit of Dose Escalation Strategies. Int J Radiat Oncol Biol Phys. 2023. PMID: 37586615. doi:10.1016/j.ijrobp.2023.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。